Actinium Pharmaceuticals Inc (ATNM)

[ronk]

I just received the shaeholder update they sent out via snail mail.

Regarding Actimab-A: "There has been resurgent interest, with global companies such as Amgen, Bayer, Boehringer, Ingelheim, Immunogen, and Seattle Genetics developing therapies for targeting CD33. Actinium seems to have the most interesting clinical data and is among the most advanced second generation CD33 targeting programs. We look forward to demonstrating that Actimab-A is best in class in the upcoming Phase 2 trial."

Some awfully big gorillas in that list. Considering Iomab-B is on the verge of PH3, big pharma doesn't like competition a whole lot. This is being held down for a reason, I believe. Here's hoping we get orphaned drug status and fast track from FDA.